<p>/PRNewswire/ -- Okami Medical 是一家開創性醫療技術公司，專注於新型血管栓塞解決方案，今天宣佈在 ALPHA 註冊中招募了第一位患者。該前瞻性多中心註冊評估 LOBO™血管閉合系統在多種外周血管疾病患者中的安全性和有效性，包括動脈出血和肺動靜脈畸形。</p>
<p>&#34;我們很榮幸能夠在 ALPHA 註冊中招募第一位患者，&#34;馬薩諸塞大學紀念醫療中心的寧城&#34;彼得&#34;李醫學博士和尼爾·J·雷斯尼克醫學博士表示。&#34;這個案例展示了 LOBO 系統在肺動靜脈畸形（PAVM）治療中的實用性。多個 PAVM 通過 LOBO 治療，每條供血動脈植入一個設備，且每條血管的過程內閉合在兩分鐘內完成。這一重要里程碑開啓了一項重大努力，以生成有意義的臨牀證據來支持 LOBO 設備。&#34;</p>
<p>LOBO 設備旨在提供對外周血管的可控機械閉合，適用於廣泛的解剖結構。該設備的專有_High Definition_ BRAID 結構優化了可輸送性、閉合性和穩定性，使醫生能夠快速實現可靠的閉合，同時保持程序的高效性。</p>
<p>&#34;LOBO 血管閉合器是一種獨特的栓塞系統，能夠在多種血管疾病中提供快速且可預測的閉合，&#34;北卡羅來納大學健康系統的現場研究員尼瑪·科卡比醫學博士表示。&#34;ALPHA 註冊的獨特結構能夠評估多種臨牀條件下的不同結果，並能夠收集關鍵的臨牀見解，幫助醫生改善栓塞患者的護理。我們為能夠為支持 LOBO 的不斷增長的臨牀證據貢獻力量而感到自豪，並繼續推動這一療法向前發展。&#34;</p>
<p>ALPHA 註冊是 Okami 更廣泛臨牀戰略中的關鍵一步，旨在提供關於 LOBO 設備在血管栓塞程序中實際使用的強有力證據。該綜合註冊將作為繼續擴展 LOBO 血管閉合系統臨牀證據的基礎，計劃在多達 30 個地點招募多達 500 名患者。</p>
<p><strong>關於 Okami Medical</strong></p>
<p>停止血流，恢復生命。這是 Okami Medical, Inc.的使命，這是一傢俬人持有的醫療設備公司，致力於通過開發創新、多功能和直觀的外周血管閉合設備來滿足患者和醫生不斷變化的需求。該公司於 2017 年由 Inceptus Medical 創立，Inceptus Medical 是一家醫療設備孵化器。欲瞭解更多信息，請訪問 www.okamimedical.com。</p>
<p>來源：</p>
<p>Okami Medical, Inc.</p>
<p>949-446-9710</p>
<p>[email protected]</p>
<p>來源 Okami Medical, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1"/></p>

OMED

CS精準醫

<p>Okami Medical 宣佈已招募首位患者參與 ALPHA 註冊，評估 LOBO™ 血管閉塞系統在各種外周血管疾病中的安全性和有效性。LOBO 設備旨在高效地提供對外周血管的控制性閉塞。該註冊將招募多達 500 名患者，覆蓋 30 個地點，為支持 LOBO 系統在栓塞手術中的應用提供臨牀證據。此舉是 Okami 提升患者護理的創新醫療解決方案戰略的一部分</p>

<p>, /PRNewswire/ -- Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO™ Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Okami Medical 是一家開創性醫療技術公司，專注於新型血管栓塞解決方案，今天宣佈在 ALPHA 註冊中招募了第一位患者。該前瞻性多中心註冊評估 LOBO™血管閉合系統在多種外周血管疾病患者中的安全性和有效性，包括動脈出血和肺動靜脈畸形。</p>
</div><p>&#34;We are honored to enroll the first patient in the ALPHA Registry,&#34; said Ningcheng &#34;Peter&#34; Li, MD and Neil J. Resnick, MD at UMass Memorial Medical Center. &#34;This case demonstrates the utility of the LOBO system in pulmonary arteriovenous malformation (PAVM) treatment. Multiple PAVMs were treated with LOBO, with one device implanted per feeding artery, and intraprocedural occlusion achieved in under two minutes per vessel. This significant milestone kickstarts a substantial effort to generate meaningful clinical evidence supporting the LOBO device.&#34;</p>
<div class="lb-trans"><p>&#34;我們很榮幸能夠在 ALPHA 註冊中招募第一位患者，&#34;馬薩諸塞大學紀念醫療中心的寧城&#34;彼得&#34;李醫學博士和尼爾·J·雷斯尼克醫學博士表示。&#34;這個案例展示了 LOBO 系統在肺動靜脈畸形（PAVM）治療中的實用性。多個 PAVM 通過 LOBO 治療，每條供血動脈植入一個設備，且每條血管的過程內閉合在兩分鐘內完成。這一重要里程碑開啓了一項重大努力，以生成有意義的臨牀證據來支持 LOBO 設備。&#34;</p>
</div><p>The LOBO device is designed to provide controlled, mechanical occlusion of peripheral vessels across a broad range of anatomies. The device's proprietary <em>HD</em> BRAID construction optimizes deliverability, occlusivity, and stability, enabling physicians to quickly achieve reliable occlusion while maintaining procedural efficiency.</p>
<div class="lb-trans"><p>LOBO 設備旨在提供對外周血管的可控機械閉合，適用於廣泛的解剖結構。該設備的專有_High Definition_ BRAID 結構優化了可輸送性、閉合性和穩定性，使醫生能夠快速實現可靠的閉合，同時保持程序的高效性。</p>
</div><p>&#34;The LOBO vascular occluder is a one-of-a-kind embolization system that delivers fast and predictable occlusion across a wide variety of vascular conditions.&#34; said Nima Kokabi, MD, site investigator at UNC Health System. &#34;The ALPHA Registry is uniquely structured to assess distinct outcomes across multiple clinical conditions, with the ability to gather key clinical insights that will help physicians enhance patient care in embolization. We are proud to contribute to the growing body of clinical evidence supporting LOBO and continue to advance this therapy forward.&#34;</p>
<div class="lb-trans"><p>&#34;LOBO 血管閉合器是一種獨特的栓塞系統，能夠在多種血管疾病中提供快速且可預測的閉合，&#34;北卡羅來納大學健康系統的現場研究員尼瑪·科卡比醫學博士表示。&#34;ALPHA 註冊的獨特結構能夠評估多種臨牀條件下的不同結果，並能夠收集關鍵的臨牀見解，幫助醫生改善栓塞患者的護理。我們為能夠為支持 LOBO 的不斷增長的臨牀證據貢獻力量而感到自豪，並繼續推動這一療法向前發展。&#34;</p>
</div><p>The ALPHA Registry is a key step in Okami's broader clinical strategy to deliver robust evidence on the real-world use of the LOBO device in vascular embolization procedures. This comprehensive registry will serve as a foundation for the continued expansion of clinical evidence on the LOBO vascular occlusion system with plans to enroll up to 500 patients across up to 30 sites.</p>
<div class="lb-trans"><p>ALPHA 註冊是 Okami 更廣泛臨牀戰略中的關鍵一步，旨在提供關於 LOBO 設備在血管栓塞程序中實際使用的強有力證據。該綜合註冊將作為繼續擴展 LOBO 血管閉合系統臨牀證據的基礎，計劃在多達 30 個地點招募多達 500 名患者。</p>
</div><p><strong>About Okami Medical</strong></p>
<div class="lb-trans"><p><strong>關於 Okami Medical</strong></p>
</div><p>Stopping flow. Restoring lives. This is the mission of Okami Medical, Inc., a privately held medical device company committed to addressing the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels. The company was created in 2017 by Inceptus Medical, a medical device incubator. For more information, please visit www.okamimedical.com.</p>
<div class="lb-trans"><p>停止血流，恢復生命。這是 Okami Medical, Inc.的使命，這是一傢俬人持有的醫療設備公司，致力於通過開發創新、多功能和直觀的外周血管閉合設備來滿足患者和醫生不斷變化的需求。該公司於 2017 年由 Inceptus Medical 創立，Inceptus Medical 是一家醫療設備孵化器。欲瞭解更多信息，請訪問 www.okamimedical.com。</p>
</div><p>Source:</p>
<div class="lb-trans"><p>來源：</p>
</div><p>Okami Medical, Inc.</p>
<div class="lb-trans"><p>Okami Medical, Inc.</p>
</div><p>949-446-9710</p>
<div class="lb-trans"><p>949-446-9710</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Okami Medical, Inc.</p>
<div class="lb-trans"><p>來源 Okami Medical, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF28855&amp;Transmission_Id=202604071606PR_NEWS_USPR_____SF28855&amp;DateId=20260407"/></p>

16:06 ET Okami Medical 宣佈首位患者已加入 ALPHA 註冊表